Search Results

You are looking at 31 - 40 of 829 items for :

  • "risk factor" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

recurrence rates. In addition, the authors seek to analyze whether this effect varies by drug or by baseline patient risk factors. Methods Literature Search Strategy The authors searched the Cochrane Controlled Trials Register (CENTRAL

Full access

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

-intent resection of CLM, it is critical to explore this issue further and develop a potential surveillance algorithm specific to this patient cohort. Within this context, the primary aim of this study was to assess the changes in recurrence risks and risk factors

Full access

Ruben Niesvizky and Ashraf Z. Badros

preventing, identifying, and managing them. Venous Thromboembolism VTE typically manifests as deep vein thrombosis (DVT) or pulmonary embolism (PE). Both cancer and cancer treatments have been identified as discrete risk factors. 1 Current evidence

Full access

Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im, and Jung-Hwan Yoon

, 30 Patients with cirrhosis are more likely to develop hepatic decompensation, resulting in hepatic failure. 5 Risk Factors for HBV Reactivation: Patient Factors, Cancer Type, and Treatment Factors Identifying risk factors for HBV reactivation

Full access

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

study period (median follow-up, 15 months [IQR, 4 months to 4.2 years]); all were attributed to the patients’ malignancies. Patient Characteristics According to Esophagitis Risk Factors We compared the clinical characteristics of patients with risk

Full access

Gary H. Lyman and David C. Dale

of AML/MDS increased significantly with the cumulative dose of epirubicin. In multivariate regression analysis, the cumulative doses of epirubicin and cyclophosphamide, but not of G-CSF, were independent risk factors for AML/MDS. Because G-CSF enables

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

point system for 4-year mortality risk: 0 to 5 points: 4% or less; 6 to 9 points is 15%; 10 to 13 points is 42%; and 14 or more points is 64%. Table 4. Independent Risk Factors for 4-Year Mortality The Adjuvant! Online program provides estimates of the

Full access

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar

cancer. BMC Cancer 2006;6:194; and Elkum N, Dermime S, Ajarim D, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007;7:222. Based on international

Full access

J. Matt McCrary, David Goldstein, Terry Trinh, Hannah C. Timmins, Tiffany Li, Jasmine Menant, Michael Friedlander, Craig R. Lewis, Mark Hertzberg, Siobhan O’Neill, Tracy King, Annmarie Bosco, Michelle Harrison, and Susanna B. Park

determine the additive effect of the significant independent variables identified in the stepwise model, each symptom or clinical abnormality represented by the independent variables was classified as a risk factor. Continuous variables were converted into

Full access

Kaustav Chatterjee, Edward Drea, Robert Smith, Mei Xue, Hunter Lambert, Jeffrey Scott, Sorena Nadaf, Simon Blanc, Prateesh Varughese, and John Verniero

following chemotherapy [1] . However, no real-world data has been published that quantifies TLS risk factors by cancer type. Methods: The Integra database of 17 community oncology accounts was queried for patients ≥18 years of age having a TLS ICD10 code